207 related articles for article (PubMed ID: 22545664)
21. Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors.
Katritzky AR; Tala SR; Lu H; Vakulenko AV; Chen QY; Sivapackiam J; Pandya K; Jiang S; Debnath AK
J Med Chem; 2009 Dec; 52(23):7631-9. PubMed ID: 19746983
[TBL] [Abstract][Full Text] [Related]
22. Trilobatin as an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope.
Yin S; Zhang X; Lai F; Liang T; Wen J; Lin W; Qiu J; Liu S; Li L
FEBS Lett; 2018 Jul; 592(13):2361-2377. PubMed ID: 29802645
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and biological evaluation of highly potent small molecule-peptide conjugates as new HIV-1 fusion inhibitors.
Wang C; Shi W; Cai L; Lu L; Wang Q; Zhang T; Li J; Zhang Z; Wang K; Xu L; Jiang X; Jiang S; Liu K
J Med Chem; 2013 Mar; 56(6):2527-39. PubMed ID: 23458727
[TBL] [Abstract][Full Text] [Related]
24. Protein design of an HIV-1 entry inhibitor.
Root MJ; Kay MS; Kim PS
Science; 2001 Feb; 291(5505):884-8. PubMed ID: 11229405
[TBL] [Abstract][Full Text] [Related]
25. Designing a soluble near full-length HIV-1 gp41 trimer.
Gao G; Wieczorek L; Peachman KK; Polonis VR; Alving CR; Rao M; Rao VB
J Biol Chem; 2013 Jan; 288(1):234-46. PubMed ID: 23184960
[TBL] [Abstract][Full Text] [Related]
26. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
[TBL] [Abstract][Full Text] [Related]
27. A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding Adnectin.
Wensel D; Sun Y; Davis J; Li Z; Zhang S; McDonagh T; Fabrizio D; Cockett M; Krystal M
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743355
[TBL] [Abstract][Full Text] [Related]
28. Development of HIV-1 fusion inhibitors targeting gp41.
Lu K; Asyifah MR; Shao F; Zhang D
Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
[TBL] [Abstract][Full Text] [Related]
29. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.
Jiang S; Debnath AK
Biochem Biophys Res Commun; 2000 Mar; 269(3):641-6. PubMed ID: 10720469
[TBL] [Abstract][Full Text] [Related]
30. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
[TBL] [Abstract][Full Text] [Related]
31. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
[TBL] [Abstract][Full Text] [Related]
32. Reduced Susceptibility to VIRIP-Based HIV-1 Entry Inhibitors Has a High Genetic Barrier and Severe Fitness Costs.
Müller JA; Glöckle A; Gawanbacht A; Geyer M; Münch J; Kirchhoff F
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925662
[TBL] [Abstract][Full Text] [Related]
33. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.
Yu F; Lu L; Du L; Zhu X; Debnath AK; Jiang S
Viruses; 2013 Jan; 5(1):127-49. PubMed ID: 23344560
[TBL] [Abstract][Full Text] [Related]
34. Protease-resistant peptide design-empowering nature's fragile warriors against HIV.
Weinstock MT; Francis JN; Redman JS; Kay MS
Biopolymers; 2012; 98(5):431-42. PubMed ID: 23203688
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
36. Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.
Zhuang M; Wang W; De Feo CJ; Vassell R; Weiss CD
J Biol Chem; 2012 Mar; 287(11):8297-309. PubMed ID: 22235115
[TBL] [Abstract][Full Text] [Related]
37. Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41.
He XY; Lu L; Qiu J; Zou P; Yu F; Jiang XK; Li L; Jiang S; Liu S; Xie L
Bioorg Med Chem; 2013 Dec; 21(23):7539-48. PubMed ID: 23673219
[TBL] [Abstract][Full Text] [Related]
38. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M
Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053
[TBL] [Abstract][Full Text] [Related]
39. [The current progress in the development of HIV-1 fusion inhibitors].
Shi WG; Jia QY; Liu KL
Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
[TBL] [Abstract][Full Text] [Related]
40. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
